WO2000052209A1 - Microarrays permettant d'identifier l'activation ou l'induction de voies biochimiques - Google Patents

Microarrays permettant d'identifier l'activation ou l'induction de voies biochimiques Download PDF

Info

Publication number
WO2000052209A1
WO2000052209A1 PCT/US2000/005260 US0005260W WO0052209A1 WO 2000052209 A1 WO2000052209 A1 WO 2000052209A1 US 0005260 W US0005260 W US 0005260W WO 0052209 A1 WO0052209 A1 WO 0052209A1
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
gene
cell
microarray
polynucleotides
Prior art date
Application number
PCT/US2000/005260
Other languages
English (en)
Inventor
Lewis T. Williams
Filippo Randazzo
Wendy Fantl
Original Assignee
Chiron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corporation filed Critical Chiron Corporation
Priority to AU33877/00A priority Critical patent/AU3387700A/en
Publication of WO2000052209A1 publication Critical patent/WO2000052209A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection

Definitions

  • This invention concerns materials and methods relating to identifying genes that play a role in regulating pathways in cells. Aspects of the invention are exemplified in diagnosis of disease, characterization of biological conditions, gene discovery, genetic analysis, and treatment of disease.
  • Proteins that play a role in disease causation or prevention are often members of a group of proteins that make up a pathway or "cascade" of biochemical reactions in the normal or diseased cell, tissue, or blood. Examples of such pathways are the apoptosis pathway of cell death; the PI3 kinase pathway; the Wnt pathway; the Ras pathway; angiogenesis and anti-angiogenesis; and the tumor necrosis factor pathway. It is possible to identify abnormal expression of individual members of these pathways and to correlate the expression with disease, such as cancer. However, it is more difficult to identify the point of regulation that has been disrupted, resulting in the disease state.
  • the invention provides a method of identifying regulatory genes for individual biochemical pathways of importance in disease such as cancer.
  • the invention also provides a method of detecting changes in expression of individual members of a biochemical pathway in a diseased cell or tissue in comparison with a normal cell or tissue.
  • the invention further provides a method of identifying genes, the expression of which is up-regulated or down-regulated by inducer molecules.
  • the invention also provides a method of identifying a pharmaceutical agent capable of altering expression of a regulatory gene, or capable of altering the activity of a regulatory gene product.
  • the invention provides a microarray having a plurality of polynucleotide molecules wherein the polynucleotide molecules represent genes encoding proteins that belong to a pathway sharing a regulatory gene or protein.
  • the invention also provides a microarray having a plurality of polynucleotide molecules, wherein the polynucleotide molecules represent genes each of which is up-regulated or down-regulated in a disease state such as cancer.
  • the invention further provides a microarray having a plurality of polynucleotide molecules, wherein a first group of the polynucleotide molecules represents genes of a first pathway, a second group of polynucleotide molecules represents genes of a second pathway, and an nth group of polynucleotide molecules represents an nth pathway; wherein each ofthe first, second or nth groups is applied to a first, second, or nth sector of the surface of the microarray support, and wherein the number of sectors is n, with n being any integer from 2 to 1000.
  • the invention provides a method of generating a detectable pattern of gene expression for genes of one biochemical pathway wherein a microarray having a plurality of polynucleotide molecules representing genes encoding protein members of a biochemical pathway is exposed to nucleic acids obtained from a selected cell or tissue, and the pattern of hybridization of nucleic acids from the cell or tissue to the polynucleotides ofthe array indicates gene expression in the cell or tissue.
  • the invention provides a method of generating a detectable pattern of gene expression for genes of two or more biochemical pathways.
  • the invention also provides a method for detecting the effect of an inducer molecule or an inhibitory molecule on expression of one or more genes of a biochemical pathway, wherein a cell or tissue is exposed to the molecule, and the nucleic acids of the cell or tissue are exposed to a microarray having polynucleotides representing genes of the pathway, and the hybridization pattern is detected and compared with the hybridization pattern of nucleic acid from a control cell or tissue.
  • the invention further provides a method for detecting the effect of an exogenous gene in a cell tranduced with the gene, wherein the pattern of gene expression of the cell is detected by hybridization of nucleic acids from the cell to polynucleotides of a microarray, wherein the polynucleotides represent genes encoding proteins of biochemical pathways, and the polynucleotides representing genes of each individual biochemical pathway are located in a defined sector ofthe microarray.
  • the invention also relates to a method of detecting the effect of a therapeutic agent administered to a mammal on the pattern of gene expression in selected cells or tissues of the mammal, wherein the pattern of gene expression of the cell is detected by hybridization of nucleic acids from the cell to polynucleotides of a microarray, wherein the polynucleotides represent genes encoding proteins of biochemical pathways, and the polynucleotides corresponding to genes of each individual biochemical pathway are located in a defined sector ofthe microarray.
  • the invention still further relates to a microarray having a plurality of molecules capable of indicating enzymatic activity, wherein the molecules are arranged in sectors, wherein each sector contains molecules capable of indicating activity of an enzyme member of a selected biochemical pathway.
  • FIG. 1 shows the Ras signal transduction pathway: a cascade of oncogenes.
  • Ras proteins function as critical intermediates between receptor (and nonreceptor) tyrosine kinases (RTKs) and downstream serine/threonine kinases (Raf-1, MEKs and MAP kinases).
  • RTKs receptor (and nonreceptor) tyrosine kinases
  • Raf-1, MEKs and MAP kinases serine/threonine kinases
  • the Grb2/SOS complex links the activated receptor tyrosine kinase with Ras.
  • a transforming version of the platelet-derived growth factor (PDGF) was first identified as a potent retro virus oncogene (v-sis).
  • Mutated versions of the alpha subunit of the heterotrimeric G protein Gi have been identified in certain human tumors and can cause transformation via Ras-dependent signaling pathways. All components designated in black have been shown to exhibit transforming potential.
  • a goal of current biomedical research is to identify regulatory proteins and genes that ultimately determine the biochemical destiny of a cell, be it cell death (apoptosis), differentiation, proliferation, quiescence, transformation to a tumor cell, metastasis to a remote site in the body, or participation in the normal function of a tissue through the production of specific proteins, antibodies, chemical messengers, and the like. Once these regulatory genes and proteins are identified, they become potential targets for intervention in the corresponding biochemical pathway. Although the genes encoding proteins of important pathways continue to be identified, adequate information is known about them now to enable the design, production, and use of the microarrays of the invention. Specific pathways and embodiment are described herein, but the invention is not limited to these embodiments.
  • the invention encompasses a method of applying related polynucleotides or proteins of a pathway in a grouped or otherwise identifiable manner on a microarray, and of detecting changes in expression of the gene or activity of a related protein in a disease state, or as a result of exposure to a therapeutic agent, a regulatory molecule, or any other relevant perturbation ofthe cell, cell extract, tissue, organ, or whole organism.
  • microarrays For the biochemical pathways, the following are non-limiting embodiments of the microarrays :
  • the microarray includes polynucleotides corresponding to genes encoding proteins of one biochemical pathway.
  • a kit of this embodiment comprises a microarray, such as a glass slide or microchip, and optionally includes reagents for the hybridization of probes to the array. This embodiment is suitable for screening cells, tissues, and any other biological sample to detect the expression of individual genes of this pathway.
  • the kit contains on the same or on a separate microarray one or more polynucleotides corresponding to genes commonly referred to as "housekeeping genes" as a control or an internal standard. 2.
  • the microarray includes polynucleotides corresponding to genes of two or more pathways.
  • each set of genes will be applied to a specific sector of the slide or microchip, with each sector containing at least 2 spots, preferably at least 4 spots, or more spots depending upon the number of different genes for that pathway.
  • Each microarray can have at least two sectors, and the number of sectors can be increased one by one to n, where n is any integer from 2 to 1000. The number of sectors is limited only by the capacity of the microchip, the sphere, the microfluidic device, etc.
  • a sector representing a specific pathway can appear once on the microarray, twice, or multiple times.
  • a kit of this embodiment is prepared as described for embodiment (1) above, except that the microarray contains polynucleotides in sectors for the present embodiment, and the microarray is designed for hybridization of the sample material to two or more pathways in one step. 3. Microarray for Detecting Enzymatic Activity
  • the microarray can contain protein or polypeptide substrates for detecting the activity of an enzyme such as a kinase.
  • the microarray contains substrates of one pathway (embodiment 1), or two or more sectors (embodiment 2), each sector containing substrates for one pathway.
  • This microarray embodiment is designed to be exposed to a cell or tissue extract, a biological fluid, or a purified protein, for detecting enzymatic activity in the extract, fluid, or protein. If the enzymatic activity is phosphorylation, the substrate on the microarray will be capable of receiving a phosphate from ATP, or other suitable phosphate donor, if active kinase is present in the sample.
  • a kit for this embodiment includes the microarray, sphere, microfluid device or the like to which at least one set of substrates, optionally at least two sectors of substrates, is attached, and optionally includes ATP or other suitable phosphate donor and a detectable signal system.
  • Nucleic acid probes or cell extracts are prepared from cell populations that have been transduced with a polynucleotide to determine the effect of the polynucleotide on expression of genes of one or more selected biochemical pathways.
  • the transduced cell can be a normal cell or a diseased cell such as a tumor cell.
  • the transduced cell can be a cell from primary normal tissue, blood, primary tumor tissue, metastatic tumor tissue, or cell culture.
  • the source of the transduced polynucleotide is not limited and can be all or part of a known gene, a polynucleotide corresponding to a known mRNA, or a polynucleotide of unknown function.
  • polynucleotide is identified through its pattern of differential expression in one or more disease states.
  • polypeptides are disclosed in applications WO99/33982, WO99/38972, WO99/58675, and US99/22226. These applications are incorporated by reference herein.
  • Nucleic acid probes or cell extracts are prepared from cell populations that have been treated with an inducer molecule, or inducer condition, defined herein as a molecule or condition that up or down-regulates gene expression or enzyme activity.
  • Nucleic acid probes or cell extracts are prepared from cells, tissues, or bodily fluids of an animal that has been exposed to a pharmaceutical agent, an inducer molecule, or an inducer condition.
  • Inducer molecules and inducer conditions are not limited to those disclosed herein, and can be any materials or treatments that may affect gene expression or enzyme activity.
  • Such inducer molecules and conditions include: 1. Molecules involved in proliferative or oncogenic pathways such as PI3 kinase; wnt; Ras, including k-Ras, h-Ras, and n-Ras; cABL; MEK; the family of FGFs; VEGF; KGF; IGFs; PDGF; and EGF;
  • Inducer Molecules that are involved in pro-angiogenic pathways such as the family of FGFs, and VEGF;
  • Inducer Molecules that are involved in anti-angiogenic pathways such as the 16K N-terminal fragment of prolactin;
  • Inducer Molecules that are small molecule antagonists or agonists of metabolic disease pathways, such as GSK 3 inhibitor that inhibits glycogen synthase kinase 3 and acts as an insulin-sensitizer, and a small molecule agonist of MC- 4R that enhances cAMP production and that may be suitable for treatment of obesity;
  • Inducer Molecules that are involved in apoptopic pathways such as the fas Ligand, and TRAIN;
  • Inducer Molecules can be cytokines and chemokines, such as IL- 2, IL-12, SLC, BLC, and members ofthe TNF family;
  • Inducer Molecules can be interferons, such as IFN- ⁇ , - ⁇ , and ⁇ ,
  • Inducer Molecules can be any ligands, such as flt3, CD40, CD28; 10. Inducer Molecules can be any active fragments of the above (1-
  • Inducing Conditions can be osmotic shock or radiation such as UV or IR; 12.
  • Other molecules can include molecules of the extracellular matrix.
  • This invention provides methods and materials for determining gene expression for genes of specific biochemical pathways, and kits including the necessary materials for practicing the method.
  • the visualization of nucleic acid hybrids indicative of gene expression, and the quantitations of the gene expression patterns, can be automated.
  • the method can be used for diagnosis of disease or diagnosis of any other biological or medical condition, for identifying new genes, for identifying expression patterns in disease conditions, and for detecting changes in expression patterns following exposure to a pharmaceutical agent or procedure.
  • the methods of the invention can be applied to any organism or to tissues or cells derived from any organism including animal or plant tissues or cells.
  • the method of the invention can be applied with equal utility to any living organism including but not limited to vertebrates and invertebrates, such as mammals including humans, birds, fish, amphibians, reptiles, insects; eucaryotes and procaryotes including fungi, bacterium and viruses; and all forms of plants.
  • the method of the invention employs probe populations of mRNA, or probe populations of cDNA derived by reverse transcription of mRNA, and also employs preselected DNA.
  • the probes may hybridize to preselected DNA molecules on the microarray, and the hybridization patterns are displayed.
  • a control gene or segment of preselected DNA to which hybrids from both sources of probes are expected to form in equal amounts can be used.
  • a gene can be, for example, any relatively invariantly expressed gene such as, but not limited to, for example, the actin gene.
  • the microarray consists of selected polynucleotides attached to a glass plate or wafer using methods known in the art. Specific examples include the glass plate or wafer array methods as described in
  • the invention is not dependent on a specific array method, and other methods can be used. These include three-dimensional arrays on spheres; microfluidic devices employing beads; and non-fixed polynucleotides. Further, any suitable detection method can be used, such as a two-color detection method using fluorescein and lissanine (Schena et al., Science, supra); and fluorescent dyes Cy5 and Cy3 (Iyer et al, Science 283-.S3, 1999).
  • Wnt is identified as a proto-oncogene in the mouse mammary gland (Tsukamoto et al., Cell .55:619, 1988). Wnt binds to its receptor and leads to inactivation of GSK, glycogen synthase kinase. GSK normally phosphorylates ⁇ - caterin, which binds directly to the intracellular domain of E-cadherin, a protein involved in cell-cell adhesion. Inactivation of GSK causes hypophosphorylation of ⁇ - caterin, which in turn interferes with its binding to APC (adenomatous polyposis coli) protein.
  • APC adenomatous polyposis coli
  • This ⁇ -caterin does not become ubiquitinated, and instead binds to Tcf/Lef (T cell factor or leukocyte enhancing factor) and is translocated to the nucleus, where it binds to the promoter/enhancer region of one or more target genes and activates transcription.
  • Tcf/Lef T cell factor or leukocyte enhancing factor
  • Additional details of this pathway are known to those skilled in the art, and will provide guidance in selecting polynucleotides for a microarray.
  • the overall pathway includes the following steps that may be detected as different in normal and cancerous cells: a. In some human tumors, levels of ⁇ -caterin are oncogenic.
  • microarrays of the invention Screening of additional tumor samples and normal tissues using the microarrays of the invention will provide additional information relevant to regulation of ⁇ -caterin and to the design of therapeutic agents.
  • a microarray having genes downstream from ⁇ - caterin one of skill can determine the precise role played by ⁇ -caterin in tumor development.
  • This pathway also provides several substrates for a microarray useful for measuring enzymatic activity: phosphorylation of ⁇ -caterin; kinase activity of GSK; phosphorylation of APC; and ubiquitination of ⁇ -caterin.
  • Such arrays can pinpoint the defect(s) in particular tumors, specifically, the ability of ⁇ -caterin to be phosphorylated or ubiquitinylated; the ability of APC to be phosphorylated; and the enzymatic activity of GSK are a few examples.
  • Such mechanisms are highly relevant to cancer, as truncations of APC, N-terminal deletions in ⁇ -caterin (deleting a GSK phosphorylation site), and point mutations of a GSK site in ⁇ -caterin have all been identified in human tumors or cancer cell lines. Furthermore, the GSK consensus site is also required for ubiquitination and degradation of ⁇ -caterin. (Aberle et al., EMBOJ 16:3191, 1997.) 5.
  • PI3 Kinase and PTEN are highly relevant to cancer, as truncations of APC, N-terminal deletions in ⁇ -caterin (deleting a GSK phosphorylation site), and point mutations of a GSK site in ⁇
  • glioblastoma multiform cell lines exhibit elevated PKB/AKT (endogenous protein kinase ⁇ ) activity. This activity was abolished by pretreatment with an inhibitor of PI3-kinase (phosphatidylinositol 3-kinase).
  • PI3-kinase phosphatidylinositol 3-kinase
  • the products of PI3-kinase activity include 3' phosphorylated inositol phospholipids, and this pathway is implicated in the inhibition of apoptosis, which relates to resistance to radiation and chemotherapy.
  • PTEN a tumor suppressor gene that encodes a phosphatase.
  • PTEN can dephosphorylate the 3' phosphate of PI (3,4,5) P3, one of the lipid products of PI3-kinase.
  • PTEN PTEN-kinase-PKB pathway through the regulation of phospholipid levels (Haas-Kogan et al., Current Biology 8: ⁇ 196, 1998). PTEN mutations have been identified in 60-70% of glioblastomas, advanced prostate cancers, and several sporadic and familial malignancies (Smith et al., Cur. Biol. 8:R24 ⁇ , 1998).
  • a variety of mutations in this pathway have been identified, such as a PI -dependent protein kinase 1 mutant that is less dependent on 3' phospholipids, and mutants of PTEN that are less able to reduce PKB/Akt activity.
  • the microarrays of the invention are designed to further elucidate the roles played by the components of the pathway, and to identify tumor cells and tissues in which defective proteins or altered gene expression play a role.
  • a large number of biological samples can be screened for, for example, decreased PTEN dephosphorylatation activity (due to decreased gene expression or to a mutation in the protein), or for activation of PK ⁇ /Akt activity by growth factors, by activated PI-3 kinase, or by PDK1.
  • a microarray designed to screen for changes in this pathway not only enables such determinations to be made, but also provides a system for efficient and rapid screening of candidate pharmaceuticals to remedy defective PTEN expression or activity.
  • AKT2 is a member of the protein kinase B (PKB) family and has been shown to have oncogenic activity.
  • PKT 2 is activated by mitogenic growth factors, including EGF, IGFI, IGFII, BFGF, PDGF, and insulin. In human ovarian cancer cells, this activation is mediated through PI3-kinase. Activated Ras and Src also induced AKT2 kinase activity through PI3-kinase. (Liu et al., Cancer Res. 58:2913, 1998).
  • An oncogene, c-p3k, which encodes a member of the catalytic subunit, pi 10, of PI3-kinase, can transform cultured chicken embryo fibroblasts (Chang et al.,
  • AKT3 is a downstream target of PI3-kinase and thus acts through this oncogenic protein to mediate mitogenic signals to promote cell proliferation and cellular transformation.
  • the Ets family of transcription factors includes nuclear phosphoproteins that are involved in cell proliferation, differentiation and oncogenic transformation.
  • the family contains proteins having a conserved DNA-binding domain that forms a highly conserved helix-turn-helix structural motif.
  • Ets proteins are targets of the Ras- MAPK signaling pathway. To direct signals to specific target genes, Ets proteins interact with other transcription factors that promote the binding of Ets proteins to composite Ras-responsive elements.
  • the ras gene is a proto-oncogene essential for the growth and differentiation of various types of cells.
  • the ras gene product, Ras is a GTP binding protein that controls signal transduction by GTP hydrolysis. Recent evidence suggests that pathways related to Ras signaling may be deregulated in breast cancer cells.
  • the components of the Ras signal transduction pathway include a number of proto- oncogene proteins that control signaling events important in cell growth and differentiation.
  • Fibroblast growth factor FGF
  • VEGF vascular endothelial growth factor
  • FGF8 FGF8
  • FGF8 is implicated in cellular transformation, and other members ofthe FGF family play roles in tumor development.
  • VEGF plays a role in angiogenesis, and is also implicated in development of cancer.
  • the microarrays of the invention provide methods of identifying the downstream effects of FGF and VEGF on specific cells and tissues.
  • Comparisons of gene expression between, for example, normal and tumor tissue samples can be accomplished by creating hybridization patterns between preselected DNA and two comparable populations of DNA or RNA probes from the tissues or cells being compared.
  • the probes can represent transcripts from comparative populations of tissues or cells.
  • the probes are differentially stained or labeled in order to make a visual comparison ofthe resulting hybridizations.
  • the information that can be derived by quantitating differential gene expression from comparable tissues includes the expression patterns of genes from a given loci, the up or down regulation of certain genes in a certain biological condition, the location of particular gene or mutation of a gene on a chromosome or loci, any of which information can also be used to clone that gene if the gene is previously unknown.
  • the probes can be mRNA, or cDNA derived from mRNA, or a modified form of these.
  • the modified form of cDNA can be, for example, derived from reverse transcription of an mRNA molecule using an oligo dT primer, in order to generate probes that contain at least the 3' sequence information of the gene, and which most likely include only the 3' end ofthe coding strand information on the cDNA first strand.
  • the cDNA can be a truncated first strand derived from the mRNA that can include sequence information that falls short of the entire coding region.
  • the truncated cDNA can contain, for example, from about 10 to about 20 nucleotides 5' of the oligo dT region (a sequence derived from the 3' end of the mRNA molecule) to about 400 or about 500 or more nucleotides 5' of the oligo dT region.
  • the probe population may contain any sequence length in between about 10 to about 500 nucleotides and may contain more than 500 nucleotides.
  • a population of cDNA derived by reverse transcription of a population of mRNA molecules using an oligo dT primer will tend to be cDNA molecules favoring a representation of the 3' end of the mRNA from which they were transcribed, and these probes can range in length from short to long, but most will contain at least a portion derived from the 3' most end of an mRNA molecule.
  • the two cell populations or tissue sources that are compared may be selected as directed by the nature of the comparison to be made for the differential presentation of gene expression.
  • mRNA or cDNA probes derived from a cancerous tissue can be compared to those derived from corresponding normal tissue, or probes derived from a population of immortal cells from a transformed cell line can be compared to the probes from normal, primary cells from a corresponding cell population.
  • probes derived from a population of immortal cells from a transformed cell line can be compared to the probes from normal, primary cells from a corresponding cell population.
  • the corresponding stimulated and unstimulated tissues or cell populations are selected as the sources from which the probes to be compared are derived.
  • stimulation can be any stimulation possible to apply to an animal, a tissue, or a cell, and can include, for example, chemical, hormonal, physical or environmental stimulation.
  • any stimulation that may alter the gene expression pattern in comparable animals, tissues, or cells, is contemplated by the invention.
  • Preselected polynucleotides are components of the microarrays.
  • the polynucleotides can be derived from normal tissue of normal animals, so that, for example, a particular biological condition can be characterized in comparison to the hybrids that form between probes from normal tissue and normal genomic DNA, and hybrids that form between abnormal tissue and the normal genomic DNA.
  • the preselected DNA can be any DNA, genomic or nongenomic, and will usually be a subportion of a genome ofthe animal being studied.
  • a chromosome, or a portion of a chromosome, including, for example several loci may be selected as the preselected DNA and placed on the microscope slide.
  • the arrays for any specific pathway will contain polynucleotides corresponding to known genes ofthe pathway
  • the invention can also be used to determine if an unknown gene plays a role in a given pathway, by using polynucleotides of that gene as part of the array for that pathway.
  • the ratio representing a differential gene expression in the two tissues that are being compared can range from 0 to infinity.
  • the ratio can be 0, where, for example the hybridization pattern of the gene from one tissue is effectively in such excess to that in the comparative tissue that, for example, 0 hybrids are formed with genes from the cancerous tissue, and, for example, 10 hybrids are formed with genes from the normal tissue, yielding a ratio of 0:10 or 0.
  • the gene therefore may be, for example, a tumor suppressor gene.
  • a ratio of infinity where, for example, a gene expressed in the cancerous tissue is in such excess to the homologous gene in the normal tissue, that the cancerous gene hybridizes to all the preselected DNA, no hybrids from the normal tissue are seen at that particular loci on the slide, and the ratio is 10:0.
  • This ratio indicates that the gene in the cancerous tissue gene is significantly up regulated as compared to that gene (or its homolog) in normal tissue, and thus may be an oncogene, and may be in part responsible for the cancerous condition.
  • the invention is practiced by creating populations of mRNA or cDNA probes from the tissues or cells, to be compared, normalizing the amount of mRNA or cDNA probes against a gene that is invariantly expressed in these tissues, preparing preselected DNA, and affixing the preselected DNA onto a microscope slide by any method known in the art to achieve such effect, including but not limited to, for example, such methods described in Meng et al., Nature Genetics 9:432-438 (1995) and Cai et al., PNAS USA 92:5164-5158 (1995), differentially labeling or staining the two populations of probes with two different optically identifiable stains or optically identifiable labels, hybridizing the two differently labeled populations onto the same microscope slide, viewing the differential staining pattern of the labeled hybrids that form with the preselected DNA on the slide, and quantitating the hybrids formed.
  • hybrids need to be normalized for their relative expression levels by conducting a control hybridization to a preselected DNA representing a gene the expression of which rarely varies from biological condition to biological condition.
  • the two populations of probes can then be adjusted for the amount of probe they contain relative to one another.
  • a hybridization is conducted between the probes and preselected DNA that is a gene the expression of which is relatively constant and predictable in all conditions, such as but not limited to, for example, the actin gene.
  • This control is conducted using equal volume of the probe population from each source, and hybridizing the labeled probes to the same slide that has the actin gene affixed.
  • the goal is to have the two populations hybridize in a ratio near 1 :1, and any variation from this ideal ratio of 1 is used to normalize the rest of the hybridization experiments, by correcting for the variation in probe amount between the two populations of probes.
  • a nucleic acid molecule or nucleic acid sequence refers to either a DNA sequence, a RNA sequence, or complementary strands thereof that comprises a nucleotide sequence.
  • the nucleic acid molecule can be a coding sequence, meaning that the polynucleotide sequence of the nucleic acid molecule encodes a protein or portion or a protein.
  • the nucleic acid molecule can also be a noncoding sequence such as an intron sequence, or any other polynucleotide sequence that is not expressed to form a functional protein.
  • nucleic acid includes all known types of nucleic acid molecules, including polynucleotide sequences, messenger RNA or mRNA sequences, complementary DNA or cDNA sequences which are generally derived by reverse transcription of an mRNA sequence, total RNA such as, for example, that RNA that can be isolated from cells or tissues, and variations, modifications and derivatives of all these.
  • equal amount refers to approximately equal amounts of probes in the two probe populations being compared, and the amounts, where they are not exactly equal but only approximately equal can be normalized to correct for any lack of equality.
  • a control gene or segment of preselected DNA that is relatively invariantly expressed, and to which hybrids from both sources of probes are expected to form in equal amounts can be used.
  • Such a gene can be, for example, any relatively invariantly expressed gene such as, but not limited to, the actin gene.
  • the hybridization pattern of the two populations of probes to the normalizing or gene should, in the best possible circumstance be hybrids that form in a ratio of 1 :1.
  • the ratio varies from a perfect ratio of 1 , for example, where the ratio of hybridization is 1 :0.9 or 1.11
  • subsequent calculations to identify a ratio of the differential hybridizations that result with the preselected DNA that is the object of the genetic analysis being conducted can be corrected or normalized with the adjusted ratio of 1.11, to reflect the relative proportions of probe amount in the two populations. Therefore, the term "equal amount” refers to an approximately equal amount, and in any event, to an amount that can be normalized or corrected for any variation from the ideal ratio of 1.
  • the method of the invention while quantitative in the sense that a quantifiable amount of hybridizations can be compared to reflect differential gene expression, does reflect an approximation, albeit a close approximation, of the relative hybridizations and so a close approximation of the relative gene expression of the two populations of probes being compared. Where a thorough study of gene expression in a given population of probes is desired, it is implicit in the method of the invention that several repeated hybridizations with the same preselected DNA should be conducted so that an average representative ratio of the gene expression levels being studied can be attained.
  • preselected polynucleotides refers to polynucleotides that are affixed to the microarray and that will form hybrids with the mRNA or cDNA probes of the invention.
  • the polynucleotide can be genomic DNA, including subsets of a genome.
  • the preselected polynucleotide can be several loci of a particular chromosome at which it is expected differential expression patterns in comparable cells or tissues may be identified.
  • the preselected polynucleotides can also be cDNA or in general any polynucleotide to which hybrids will form in contact with nucleic acid probes.
  • preselected polynucleotide molecules are polynucleotides derived from a vertebrate or invertebrate species, such as a mammalian gene, including a human gene, an avian gene, a fish gene, an amphibian gene, a reptilian gene; polynucleotides derived from eucaryotes and procaryotes, such as a fungal gene or a bacterial gene; polynucleotides derived from a virus; polynucleotides derived from an insect; and polynucleotides derived from a plant.
  • the preselected polynucleotides represent genes encoding proteins that are members of a biochemical pathway or cascade.
  • diseased refers to tissue from an organism that is afflicted with an adverse biological, physiological, genetic, or molecular biological condition.
  • the tissue taken from the organism, and the cells that make up the tissue can also be considered diseased, and can manifest the disease before the entire organism is considered.
  • the optimal function can be indicated by any number of indicia, including but not limited to an up or down regulation in gene expression.
  • the disease can also be identified by a variety of other parameters, including but not limited to the condition of the organism generally, the condition of tissue taken from the organism as compared to corresponding normal tissue, and the condition of cells that make up tissue taken from the organism.
  • the disease can be an identified or as yet unidentified disease, and may be a disease that carries a variety of phenotypes, genotypes, or physiological or biological effects.
  • the disease may be in the initial stages of the progression of the disease, or may in the later stages.
  • the disease may be infectious or noninfectious.
  • inflamed refers to a condition of tissue in which the tissue condition indicates that the organism is experiencing a local immune reaction known as inflammation, or inflammatory response.
  • An inflammatory reaction may occur because of any number of causes, including but not limited to infection, the presence of nonself antigen in the organism, an allergen, an irritation, chemical treatment or poisoning, a therapy or treatment for another condition that induces the side effect of inflammation, a complement mediated reaction, an allergic reaction, a T- cell reaction, and an antibody reaction.
  • the condition of inflammation in a tissue may be short lived, or chronic, and it is possible that the true causes of the inflammation are unknown.
  • a diagnosis of inflammation may be made in a variety of circumstances by a variety of methods.
  • the term cytokines as used herein refers to a broad class of molecules that are capable of promoting cell growth and division.
  • the class includes, but is not limited to the interleukins including IL-1, IL-2, IL-3, IL-6, IL-8, and IL-10, colony stimulating factors such as, for example GM-CSF, and interferon such as, for example, IFN-1.
  • Stimulation by cytokines can occur by inducing cytokine production endogenously in the cells, tissue, or organism, or by administering exogenous cytokines to the organism, tissue or cells.
  • growth factor refers to a member of a class of molecules that are unified by their ability to promote cell growth.
  • Exemplary growth factors include, but are not limited to, for example, platelet derived growth factor (PDGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), transforming growth factor (TGF), epithelial growth factor (EGF), and nerve growth factor (NGF).
  • PDGF platelet derived growth factor
  • FGF fibroblast growth factor
  • IGF insulin-like growth factor
  • TGF transforming growth factor
  • EGF epithelial growth factor
  • NGF nerve growth factor
  • Growth factors have various mechanisms of action and various structures and are characterized only by the capability to promote cell growth.
  • the invention also embodies the use of growth factors that are not presently known, but which may be discovered at a later date.
  • differentiation factor refers to a molecule that can cause a cell or tissue to differentiate, i.e., to become more specialized in its function. Because differentiation is sometimes considered a process specific to a particular pathway or to a particular final differentiated result, differentiation factors can be specific to tissues or cells in which the differentiation occurs.
  • the term physically stimulated as used herein refers to any physical stimulation that can be applied to an organism, a tissue, or a cell.
  • Physical stimulation can include, but is not limited to, for example radiation, electrical, heat, cold, light, rigor, starvation of any kind, environmental stimulus, the passage of time, or in general any physical stimulus that is believed might alter the gene expression of a given cell, tissue, or organism.
  • chemically stimulated refers to any chemical stimulation that can be applied or administered to an organism, a tissue, or a cell.
  • Chemical stimulation can include, but is not limited to, for, example, administration of toxins, drugs, small molecules, inhibitors, plants or chemicals derived from plants. Chemical stimulation may also include stimulation by more than one chemical, either, for example, by administering more than one chemical at the same time, or by administering the chemicals consecutively.
  • optically detectable marker refers to any of a number of optically detectable markers, labels or stains that can affix, bond, or otherwise identify a nucleic acid molecule, and which can allow visualization of the presence of the nucleic acid molecule to which the label is affixed.
  • the label for labeling nucleic acid molecules can be any label that will visually identify the nucleic acid molecule, including, but not limited to, for example, fiuorescein and rhodamine.
  • hybridization refers to the formation of a binding pair of molecules.
  • the binding pair can be a pair of molecules including, for example, a DNA/DNA pair, or a DNA/RNA pair, in which the components of the pair bind specifically to each other with a higher affinity than to a random molecule.
  • the pairing between nucleic acids molecules can be between two single stranded molecules, or a single and a double stranded molecule.
  • An optically detectable label can be attached to one or both of the hybridizing molecules for visualization of the molecules.
  • Hybridization can occur upon contact of the two molecules of the binding pair, which contact may occur, for example, on a microscope slide, a glass plate, in a tube, a petri dish, on plastic or other synthetic material, and in vitro or in vivo.
  • the term "specific binding" used in reference to interaction between two molecules to form a binding pair indicates a higher affinity binding and a lower dissociation constant than nonspecific binding, thus, distinguishing specific binding from background binding.
  • the hybridization conditions for forming the DNA/DNA hybrids or the RNA/DNA hybrids ofthe invention can be any hybridization condition that will allow a hybrid to form, and can include, but are not limited to those techniques described in Ausubel et al.
  • kit refers to a package containing the specified material and includes printed instructions for use of the material.
  • a kit can be a diagnostic kit for identifying the characteristics or progress of a disease by identifying up or down regulation of specific genes in certain diseases.
  • Printed instructions may be written or printed on paper or other media, or committed to electronic media such as magnetic tape, computer-readable disks or tape, CD-ROM, and the like. Kits may also include plates, tubes, microscope slides, stain, dishes, diluents, solvents, wash fluid or other conventional reagents, and may also include polynucleotide materials.
  • the method of the invention can be used to isolate new genes that are identified during probe hybridization with preselected polynucleotide to result in a gene expression pattern that highlights a particular gene or group of genes.
  • the isolation of new genes can be accomplished by identifying the preselected polynucleotide that forms the hybrid, isolating that piece of polynucleotide, cloning the polynucleotide sequence into a vector, and using the sequence to probe a cDNA library.
  • the gene that hybridizes to preselected polynucleotide can then be cloned by standard molecular biology techniques.
  • the information about any gene so identified can be used as a basis for developing therapeutic strategies to fight the disease or biological condition in which the gene is up regulated or down regulated, or which is implicated in the mechanism of the disease or condition.
  • the effectiveness of any such therapy can be determined by reapplication of differential presentation of gene expression using probes derived from the treated tissue as compared to probes from either the nontreated normal tissue, or the nontreated diseased tissue. Such analysis of the effectiveness of any therapy or treatment can be applied using the method of the invention at any point during the course of a therapy or treatment.
  • the method of the invention may also be used to study differential expression of plant genes for various uses in understanding plant development, and plant disease and for genetically engineering plants.
  • the tissues that can be studied by the method of the invention include any tissues from which nucleic acid (DNA or RNA) can be extracted, or from which cDNA can be generated.
  • the nucleic acid can be generated from the cancer tissue, for example, in the case of liver cancer, from liver tumor tissue, and can be compared with normal liver tissue. Similar comparisons can be made between normal and affected or afflicted tissues in all cases where the method of the invention is applied to treat or diagnose a disease or other biological condition.
  • Comparisons can also be made between treated and untreated tissues, so that, for example, comparisons can be made between the expression patterns of tissue stimulated with, for example, cytokines, growth factors, or differentiation factors, or the same tissues unstimulated.
  • Other stimulus can include, for example, chemical or physical stimuli, or environmental stimuli.
  • Microarray Preparation Amino-modified PCR products are suspended at a concentration of 0.5 mg/ml in 3x standard saline citrate (SSC) and arrayed from 96- well micro-titer plates onto sialylated microscope slides (CEL Associates, Houston) using high-speed robotics. cDNAs are arrayed in 1.0-cm 2 areas. Printed arrays are incubated for 4 hours in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 minute, twice in H 2 O for 1 minute, and once for 5 minutes in sodium borohydride solution (1.0 g of NaBH 4 dissolved in 300 ml of PBS and 100 ml of 100% ethanol). The arrays are submerged in H 2 O for 2 minutes at 95°C, transferred quickly into 0.2% SDS for 1 minute, rinsed twice in H 2 O, air dried, and stored in the dark at 25°C.
  • SSC standard saline citrate
  • Tissue mRNAs are purchased (CLONTECH). Cellular mRNA is isolated using methods as described by Schena et al., Rroe. Nat 'l Acad. Sci. 95:10614 (1996). Probes are made as described in Schena et al. with several modifications.
  • the reverse transcriptase used is Superscript II RNase H (GIBCO).
  • the Cy5-dCTP is purchased from Amersham. Each reverse transcription reaction contains 3.0 ⁇ g of total human mRNA. For quantitation, the mRNAs are doped into the reverse transcription reaction at ratios of 1 :100,000, 1 :10,000, and 1 :1000 (wt/wt) respectively.
  • Probe mixtures contain cDNA products derived from 3 ⁇ g of total mRNA, suspended in 5.0 ⁇ l of hybridization buffer (5 x SSC plus 0.2% SDS). Hybridization and Scanning. Probes are hybridized to 1.0-cm 2 microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60°C in a hybridization chamber as described in Schena et al. Arrays are washed for 5 minutes at room temperature (25°C) in low stringency wash buffer (1 x SSC/0.2% SDS), then for
  • the cDNA library is made with mRNA from selected cells, for example cells transduced with polynucleotide sequence of unknown function. Inserts >600bp are cloned into the lambda vector ⁇ YES-R to generate 107- 108 recombinants. Bacterial transformants are obtained by infecting E. coli strain JM107/ ⁇ KC. Colonies are picked at random and propagated in a 96-well format, and minilysate DNA is prepared by alkaline lysis using REAL preps (Qiagen, Chatsworth, CA).
  • Inserts are amplified by PCR in a 96-well format using primers (PAN132, 5'- CCTCTATACTTTAACGRCAAGG; and PAN133, 5'-TTGTGTGGAATTGRGA- GCGG) complementary to the ⁇ YES polylinker and containing a six-carbon amino modification (Glen Research, Sterling, VA) on the 5' end.
  • primers PAN132, 5'- CCTCTATACTTTAACGRCAAGG; and PAN133, 5'-TTGTGTGGAATTGRGA- GCGG
  • PCR products are purified in a 96-well format using QIAquick columns (Qiagen).
  • a microarray for an Ets-related pathway is prepared using pathway genes as described in detail in Wasylyk et al., Trends in Biochem. Sci. 23:213 (1998).
  • the Ets family of transcription factors includes proteins that serve as targets for Ras-induced phosphorylation.
  • a suitable array will comprise polynucleotides of the following genes:
  • MAP kinase members ERK, JNK, and p38/RK Ets family members ETS, YAN, ELG, PEA3, ERF and TCF
  • This pathway is also suitable for preparing a microarray of enzyme substrates, specifically kinase substrates ( Figure 1). As described by Wasylyk et al., phosphorylation of an Ets protein enhances its ability to activate transcription. This in turn is a product of upstream kinase activation of MAP kinase members that phosphorylate the Ets proteins.
  • This pathway can elucidate changes in gene expression and protein phosphorylation that are brought about by putative tumorigenic stimuli such as growth factors.
  • the role of this pathway in individual cancers can be studied, as can the effect of an agent administered to inhibit the pathway.
  • Figure 1 illustrates in schematic form the Ras signal transduction pathway. It is believed that other members ofthe family of genes may be oncogenes. (Clark et al., Breast Cancer Research and Treatment 55:133, 1995.)
  • a microarray comprising genes upstream and downstream from ras, plus one or more genes of unknown function that are upregulated in tumor cells, can be used to identify whether the unknown genes are regulated by the same factors that regulate the ras pathway.
  • a microarray can comprise polynucleotides relating to one pathway, or sectors each containing genes relating to one pathway. Additional information for preparing such microarrays includes: Marshall et al., Ann. Oncol. 6:563, 1995 (ras pathway); Vojtek et al., J. Biol. Chem. 275:19925, 1998 (ras pathway and related mutations); Chiarugi et al., Int. J. Mol. Med. 2:715, 1998 (cyclooxygenase pathway; angiogenesis); Shimizu et al., Hum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un microarray contenant des polynucléotides qui représentent des gènes codant pour des protéines participant à une ou à plusieurs voies ou cascades biochimiques. Les microarrays peuvent aussi contenir des substrats destinés à des enzymes faisant partie desdites voies ou cascades. Ils sont utilisés avec des techniques permettant de détecter les modifications de l'expression spécifique d'un gène ou d'une fonction spécifique d'une protéine en rapport avec une maladie ou le traitement d'une maladie.
PCT/US2000/005260 1999-03-02 2000-02-28 Microarrays permettant d'identifier l'activation ou l'induction de voies biochimiques WO2000052209A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33877/00A AU3387700A (en) 1999-03-02 2000-02-28 Microarrays for identifying pathway activation or induction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12243199P 1999-03-02 1999-03-02
US60/122,431 1999-03-02

Publications (1)

Publication Number Publication Date
WO2000052209A1 true WO2000052209A1 (fr) 2000-09-08

Family

ID=22402678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/005260 WO2000052209A1 (fr) 1999-03-02 2000-02-28 Microarrays permettant d'identifier l'activation ou l'induction de voies biochimiques

Country Status (2)

Country Link
AU (1) AU3387700A (fr)
WO (1) WO2000052209A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
EP1270740A1 (fr) * 2001-06-29 2003-01-02 SIRS-Lab GmbH Biopuce et son utilisation pour la détermination de l'inflammation
US6576478B1 (en) 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US6682942B1 (en) 1998-07-14 2004-01-27 Zyomyx, Inc. Microdevices for screening biomolecules
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
WO2004079000A1 (fr) * 2003-03-07 2004-09-16 National Research Council Of Canada Determination de la fonction de proteines mammaliennes par analyse de profils globaux d'expression genique
US20110262025A1 (en) * 2010-02-05 2011-10-27 Bradley Bryan Jarrold Cosmetic Compositions and Methods for Maintaining and Improving Barrier Function of the Stratum Corneum and to Reduce the Visible Signs of Aging in Skin
US8110364B2 (en) 2001-06-08 2012-02-07 Xdx, Inc. Methods and compositions for diagnosing or monitoring autoimmune and chronic inflammatory diseases
US20120258076A1 (en) * 2009-12-16 2012-10-11 Hitachi Chemical Research Center, Inc. Method for characterizing host immune funtion by ex vivo induction of offensive and defensive immune markers
US20130042333A1 (en) * 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
US9150920B2 (en) 2010-05-07 2015-10-06 Hitachi Chemical Co., Ltd. Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers
US20160090628A1 (en) * 2014-09-25 2016-03-31 The Regents Of University Of Michigan Detection of mineralocorticoid receptor activation and personalized antihypertensive therapy based thereon
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006277A1 (fr) * 1995-08-09 1997-02-20 The Regents Of The University Of California Procedes destines a la prospection systematique de medicaments
WO1997013877A1 (fr) * 1995-10-12 1997-04-17 Lynx Therapeutics, Inc. Mesure de profils d'expression genique pour evaluer la toxicite
WO1998053103A1 (fr) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Ensembles d'acide nucleique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006277A1 (fr) * 1995-08-09 1997-02-20 The Regents Of The University Of California Procedes destines a la prospection systematique de medicaments
WO1997013877A1 (fr) * 1995-10-12 1997-04-17 Lynx Therapeutics, Inc. Mesure de profils d'expression genique pour evaluer la toxicite
WO1998053103A1 (fr) * 1997-05-21 1998-11-26 Clontech Laboratories, Inc. Ensembles d'acide nucleique

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682942B1 (en) 1998-07-14 2004-01-27 Zyomyx, Inc. Microdevices for screening biomolecules
US6475808B1 (en) 1998-07-14 2002-11-05 Zyomyx, Incorporated Arrays of proteins and methods of use thereof
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6576478B1 (en) 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US6582969B1 (en) 1998-07-14 2003-06-24 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US6596545B1 (en) 1998-07-14 2003-07-22 Zyomyx, Inc. Microdevices for screening biomolecules
US6630358B1 (en) 1998-07-14 2003-10-07 Zyomyx, Incorporated Arrays of proteins and methods of use thereof
US6475809B1 (en) 1998-07-14 2002-11-05 Zyomyx, Incorporated Protein arrays for high-throughput screening
US8110364B2 (en) 2001-06-08 2012-02-07 Xdx, Inc. Methods and compositions for diagnosing or monitoring autoimmune and chronic inflammatory diseases
EP1270740A1 (fr) * 2001-06-29 2003-01-02 SIRS-Lab GmbH Biopuce et son utilisation pour la détermination de l'inflammation
WO2004079000A1 (fr) * 2003-03-07 2004-09-16 National Research Council Of Canada Determination de la fonction de proteines mammaliennes par analyse de profils globaux d'expression genique
US20120258076A1 (en) * 2009-12-16 2012-10-11 Hitachi Chemical Research Center, Inc. Method for characterizing host immune funtion by ex vivo induction of offensive and defensive immune markers
US20110262025A1 (en) * 2010-02-05 2011-10-27 Bradley Bryan Jarrold Cosmetic Compositions and Methods for Maintaining and Improving Barrier Function of the Stratum Corneum and to Reduce the Visible Signs of Aging in Skin
US9150920B2 (en) 2010-05-07 2015-10-06 Hitachi Chemical Co., Ltd. Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers
US20130042333A1 (en) * 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
US20160090628A1 (en) * 2014-09-25 2016-03-31 The Regents Of University Of Michigan Detection of mineralocorticoid receptor activation and personalized antihypertensive therapy based thereon
US11028443B2 (en) 2015-08-31 2021-06-08 Showa Denko Materials Co., Ltd. Molecular methods for assessing urothelial disease

Also Published As

Publication number Publication date
AU3387700A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
Pallas et al. Association of polyomavirus middle tumor antigen with 14-3-3 proteins
Karin Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors
Michaud et al. 14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3-and Ras-independent manner
Raffaello et al. Denervation in murine fast-twitch muscle: short-term physiological changes and temporal expression profiling
US6258536B1 (en) Expression monitoring of downstream genes in the BRCA1 pathway
Park et al. Gene profile of replicative senescence is different from progeria or elderly donor
Spencer et al. Induction of neurite extension and survival in pheochromocytoma cells by the Rit GTPase
WO2000052209A1 (fr) Microarrays permettant d'identifier l'activation ou l'induction de voies biochimiques
WO1991019008A1 (fr) Une famille de proteinekinases map2
KR20090027735A (ko) Ｔａｋ1 억제제를 사용한 암 치료 방법
KR20030076695A (ko) 진단에서의, 그리고 암에서 치료 표적으로서의 ｔｔｋ
CN114032311A (zh) Mettl3在aml化疗耐药性中的应用
US20140087969A1 (en) PIM-3 Kinase as a Target for Type 2 Diabetes Mellitus
Dayem et al. Early gene expression in wounded human keratinocytes revealed by DNA microarray analysis
US20110151469A1 (en) Interferon epsilon (ifne1) as a marker for targeted cancer therapy
EP2460890A1 (fr) Gpnmb/Osteoactivin en tant que cible de médicament et biomarqueur pour les maladies cardiaques
US6413717B1 (en) Methods for indentifying anti-cancer agents
US20060024658A1 (en) Composition and methods for evaluating an organism's response to alcohol or stimulants
Macdonald et al. PPARα-dependent alteration of GRP94 expression in mouse hepatocytes
RU2316598C2 (ru) Киназа pim-3 в качестве мишени для сахарного диабета типа 2
US20040110177A1 (en) Method for identifying functional nucleic acids
AU2002249170A1 (en) Method for identifying functional nucleic acids
AU2003202579B2 (en) PIM-3 kinase as a target for type 2 diabetes mellitus
JP2003230388A (ja) 糖・脂質代謝異常疾患マーカーおよびその利用
Huiyu et al. Gene expression pattern of signal transduction in chronic myeloid leukemia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase